PMID- 34433731
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR  - 20220117
IS  - 1349-3329 (Electronic)
IS  - 0040-8727 (Linking)
VI  - 254
IP  - 4
DP  - 2021 Aug
TI  - Nephrotoxicity of Immune Checkpoint Inhibitors: A Disproportionality Analysis 
      from 2013 to 2020.
PG  - 275-282
LID - 10.1620/tjem.254.275 [doi]
AB  - Nephrotoxicity occasionally occurs during treatment with immune checkpoint 
      inhibitors (ICIs). Few related studies compare the differences between these 
      drugs. This study aimed to systematically characterize nephrotoxicity after ICI 
      initiation. Data were extracted from the US FDA Adverse Event Reporting System 
      (FAERS) database. Disproportionality analysis, including information components 
      (ICs) and reporting odds ratios (RORs), was performed to determine the potential 
      renal toxicity of ICIs. A total of 7,204 reports of renal adverse events (AEs) 
      were identified in the FAERS database. Renal AEs were most commonly reported for 
      nivolumab (46.84%). Strong signals were detected in male patients combined with 
      ICIs. In the clinical application of ICIs, attention should be paid to patients, 
      especially male patients, with acute kidney injury, nephritis, autoimmune 
      nephritis and other nephrotoxic AEs. The use of ICIs is likely to aggravate their 
      condition.
FAU - Qu, Jiaming
AU  - Qu J
AD  - School of Pharmacy, Shenyang Pharmaceutical University.
FAU - Ding, Yanming
AU  - Ding Y
AD  - School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical 
      University.
FAU - Jiang, Kaiwen
AU  - Jiang K
AD  - School of Pharmacy, Shenyang Pharmaceutical University.
FAU - Hao, Junxia
AU  - Hao J
AD  - School of Pharmacy, Shenyang Pharmaceutical University.
FAU - Li, Yuanzhi
AU  - Li Y
AD  - School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical 
      University.
FAU - Zhang, Aijun
AU  - Zhang A
AD  - School of Pharmacy, Shenyang Pharmaceutical University.
FAU - Li, Zhaohang
AU  - Li Z
AD  - School of Pharmacy, Shenyang Pharmaceutical University.
FAU - Qi, Guanpeng
AU  - Qi G
AD  - School of Pharmacy, Shenyang Pharmaceutical University.
FAU - Xu, Ze
AU  - Xu Z
AD  - School of Pharmacy, Shenyang Pharmaceutical University.
FAU - Liu, Xin
AU  - Liu X
AD  - School of Pharmacy, Shenyang Pharmaceutical University.
FAU - Ma, Juman
AU  - Ma J
AD  - School of Pharmacy, Shenyang Pharmaceutical University.
FAU - Bi, Kaishun
AU  - Bi K
AD  - School of Pharmacy, Shenyang Pharmaceutical University.
FAU - Li, Zuojing
AU  - Li Z
AD  - School of Medical Devices, Shenyang Pharmaceutical University.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Tohoku J Exp Med
JT  - The Tohoku journal of experimental medicine
JID - 0417355
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Humans
MH  - *Immune Checkpoint Inhibitors
MH  - Male
MH  - Nivolumab/adverse effects
MH  - Pharmacovigilance
MH  - United States/epidemiology
MH  - United States Food and Drug Administration
OTO - NOTNLM
OT  - Adverse Event Reporting System
OT  - adverse events
OT  - disproportionality analysis
OT  - immune checkpoint inhibitors
OT  - nephrotoxicity
EDAT- 2021/08/27 06:00
MHDA- 2022/01/18 06:00
CRDT- 2021/08/26 05:38
PHST- 2021/08/26 05:38 [entrez]
PHST- 2021/08/27 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
AID - 10.1620/tjem.254.275 [doi]
PST - ppublish
SO  - Tohoku J Exp Med. 2021 Aug;254(4):275-282. doi: 10.1620/tjem.254.275.